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Abstract
Epidemiological studies suggest a relationship between blood lipids and immune-mediated
diseases, but the nature of these associations is not well understood. We used genome-wide
association studies (GWAS) to investigate shared single nucleotide polymorphisms (SNPs)
between blood lipids and immune-mediated diseases. We analyzed data fromGWAS
(n~200,000 individuals), applying new False Discovery Rate (FDR) methods, to investigate
genetic overlap between blood lipid levels [triglycerides (TG), low density lipoproteins (LDL),
high density lipoproteins (HDL)] and a selection of archetypal immune-mediated diseases
(Crohn’s disease, ulcerative colitis, rheumatoid arthritis, type 1 diabetes, celiac disease, pso-
riasis and sarcoidosis). We found significant polygenic pleiotropy between the blood lipids
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and all the investigated immune-mediated diseases. We discovered several shared risk loci
between the immune-mediated diseases and TG (n = 88), LDL (n = 87) and HDL (n = 52).
Three-way analyses differentiated the pattern of pleiotropy among the immune-mediated
diseases. The new pleiotropic loci increased the number of functional gene network nodes
representing blood lipid loci by 40%. Pathway analyses implicated several novel shared
mechanisms for immune pathogenesis and lipid biology, including glycosphingolipid synthe-
sis (e.g. FUT2) and intestinal host-microbe interactions (e.g. ATG16L1). We demonstrate a
shared genetic basis for blood lipids and immune-mediated diseases independent of environ-
mental factors. Our findings provide novel mechanistic insights into dyslipidemia and im-
mune-mediated diseases and may have implications for therapeutic trials involving lipid-
lowering and anti-inflammatory agents.
Introduction
Plasma concentrations of low-density lipoprotein (LDL) cholesterol, high-density lipoprotein
(HDL) cholesterol and triglycerides (TG) are heritable risk factors for cardiovascular disease
and important pharmacological targets for prevention strategies. Several lines of evidence sug-
gest a relationship between lipid biology and the immune system. For example, clinical and epi-
demiological data suggest an association between blood lipid levels and immune-mediated
diseases, including Crohn’s disease (CD), ulcerative colitis (UC), rheumatoid arthritis (RA),
type 1 diabetes (T1D), celiac disease (CeD), psoriasis (PSOR) and sarcoidosis (SARC)[1–5]. In
addition to diet and other environmental factors, it is possible that the increased occurrence of
dyslipidemia and subsequent atherosclerosis in patients with immune-mediated diseases could
reflect genetically determined factors influencing both lipid metabolism and immune-mediated
disorders that cannot be elucidated by observational epidemiological and clinical studies.
Genetic epidemiology approaches offer great promise for delineating the underlying basis of
shared phenotypic correlations[6]. Traditional genome wide association studies (GWAS) have
provided valuable insights into the role of biologic pathways in disease pathogenesis and identi-
fied several loci in CD[7], UC[8], RA[9], T1D[10], CeD[11], PSOR[12], and SARC[13], as well
as in regulation of TG, HDL and LDL cholesterol[14]. Combining GWAS data from various
phenotypes, it is now feasible to determine the association of single nucleotide polymorphisms
(SNPs) with more than one phenotype (genetic pleiotropy)[15]. This may enable identification
of genetic factors responsible for shared disease mechanisms[15–21].
This genetic epidemiology approach may be useful for elucidating the genetic basis of the
clinically observed association between dyslipidemia, immune-mediated diseases and inflam-
mation. Abnormal lipid profiles may occur in individuals before the onset of immune-mediat-
ed diseases, suggesting a potential pathogenic relationship[22]. Specifically, altered lipid levels
and functions have been implicated in several immune-mediated diseases and inflammatory
responses[23], including anti-inflammatory effects of HDL cholesterol and inflammatory re-
sponses of modified LDL cholesterol[24]. Conversely, inflammation has been found to modify
lipid levels and lipoprotein composition at least partly through modulation of scavenger recep-
tors, cholesterol efflux mechanisms and various enzymes in lipid metabolism such as lipopro-
tein lipase. This bidirectional interaction between lipid biology and inflammation is a major
pathogenic feature of atherosclerosis and related metabolic disorders[25] and is accelerated in
many autoimmune and inflammatory disorders[26].
Pleiotropy Immune and Lipid Pathobiology
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Here, we applied a recently-developed genetic epidemiology framework [15–21] to system-
atically interrogate the potentially shared genetic basis between immune-mediated diseases
(CD, UC, RA, T1D, CeD, PSOR, SARC) and blood lipid levels (TG, LDL, HDL). Using our
new methodology, we have previously identified genetic pleiotropy (defined as SNPs associated
with more than one phenotype) between a number of diseases/phenotypes and identified vari-
ants that significantly increase the risk of schizophrenia[16,17,19], bipolar disorder[19], hyper-
tension[18], and primary sclerosing cholangitis[21] and prostate cancer[20].
Materials and Methods
Ethics Statement
All the GWAS of the different phenotypes investigated in the current study were approved by
the local Ethic committee for each of the sub-samples included. Further, the Norwegian IRB
for the South East region has evaluated the current protocol and found that no additional IRB
approval needed, because of no individual data was used.
Participant Samples
We obtained GWAS results in the form of summary statistic p-values from the original publi-
cations or from collaborating GWAS consortia (Table A in S1 File)[7–14]. We utilized summa-
ry statistics (p-values and z-scores) for conditional and conjunction FDR analyses. Details of
the inclusion criteria and phenotype characteristics of the different GWAS are described in the
original publications[7–14,27]. We corrected all p-values for inflation using a recently devel-
oped genomic control procedure[15,16,19]. The blood lipid GWAS of TG, HDL and LDL in-
volved the same population. However, in the current analyses, we did not examine pleiotropy
among the lipid traits. Approximately 2,000 to 3,000 overlapping controls were present be-
tween the RA, UC and CD GWAS. We used the recently published blood lipid GWAS[28]
(n = 188,577) as confirmation sample, and included the cigarettes per day (CPD) GWAS[29]
(n = 74,053) as a negative control.
Statistical Analyses
Quantifying enrichment based on conditional Q-Q Plots. A common method for visual-
izing the enrichment of statistical association relative to that expected under the global null hy-
pothesis is through Q-Q plots. Q-Q plots present nominal p-values obtained from GWAS
summary statistics as a function of empirical p-values expected under the global null hypothe-
sis. We constructed conditionalQ-Q plots where we display the distribution of summary statis-
tics for the primary trait conditional on different levels of significance in a secondary trait (i.e.
associated with a immune mediated disease). Associations in the primary trait were condi-
tioned on a p-value threshold in the secondary traits, i.e—log10 p-value>1,>2, and>3. If en-
richment of the blood lipid trait is present among SNPs that are significantly associated with
the immune trait (pleiotropic enrichment), there will be successive leftward deflections in the
conditional Q-Q plot as levels of association with the immune trait increase[15–21]. In Figures
A-C in S1 File we show Q-Q plots for the blood lipids GWAS conditioning on the significance
in the immune-mediated diseases (CD, UC, RA, T1D, CeD, PSOR, SARC). To control for spu-
rious enrichment due to large LD blocks, we calculated FDR after random pruning (see Below).
Detection of shared associations using conjunction FDR. For the detection of pleiotro-
pic associations we used a genetic epidemiology framework based on the conjunction false dis-
covery rate (conjFDR). We have previously used this approach to identify shared genetic risk
loci between psychiatric, cardiovascular, immune-related diseases and cancer[15–20].
Pleiotropy Immune and Lipid Pathobiology
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Conjunction FDR, denoted by FDRtrait1& trait2 is defined as the posterior probability that a SNP
is null for either phenotype or both simultaneously, given the p-values for both traits are as
small or smaller than the observed p-values[15–20]. We obtained a conservative estimate of
conjunction FDR via the conditional FDR (Tables B-D in S1 File). The conditional FDR, de-
noted by FDRtrait1|trait2, is defined as the posterior probability that a given SNP is null for the
first trait given that the p-values for both traits are as small or smaller than the observed p-val-
ues[15–20]. A conservative estimate of the conjunction FDR FDRtrait1& trait2 is given by the
maximum statistic[30] in taking the maximum of FDRtrait1|trait2 and FDRtrait2|trait1. While the
conditional FDR can be used to reorder SNPs based on the additional information provided by
the co-morbid secondary traits, the conjunction FDR pinpoints pleiotropic loci, since a low
conjunction FDR is only possible if there is an association with the two traits of interest jointly.
To visualize the localization of the pleiotropic genetic variants associated with both blood
lipids and immune-mediated diseases, we used a ‘Conjunction FDRManhattan plot’, showing
all SNPs with a significant conjunction FDR within an LD block in relation to their chromo-
somal location. As illustrated in Figs 1, 2 and 3, the enlarged data points represent the signifi-
cant SNPs (FDR trait1& trait2< 0.05), whereas the small points represent the non-significant
SNPs. All SNPs without pruning are shown, and the strongest signal in each LD block is encir-
cled in black. The strongest signal was identified after ranking all SNPs based on the
Fig 1. ‘Conjunctional FDRManhattan plot’ of conjunctional (FDR<0.05) values for triglycerides. Conjunctional—log10(FDR) values for triglycerides
(TG) and Crohn’s Disease (CD), ulcerative colitis (UC), rheumatoid arthritis (RA), type 1 diabetes (T1D), celiac disease (CeD), psoriasis (PSOR) and G)
sarcoidosis (SARC) were plotted along their chromosome locations. SNPs with conjunctional FDR < 0.05 (i.e.,—log10 FDR > 1.3) are shown with enlarged
data points. A black circle around the enlarged data points indicates the most significant SNP in each LD block and this SNP was annotated with the closest
gene which is listed above the symbols in each locus, except for the Major Histocompatibility Complex (MHC) region on chromosome 6. The figure shows the
localization of 88 TG loci. Details for the associated loci outside of chromosome 6 are shown in Table E in S1 File.
doi:10.1371/journal.pone.0123057.g001
Pleiotropy Immune and Lipid Pathobiology
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conjunction FDR and removed SNPs in LD r2> 0.2 with any higher ranked SNP (Figs 1, 2
and 3 and Figures U-W in S1 File).
We further evaluated the clustering of the different phenotypes by constructing color-coded
heat maps to illustrate the number of conjunctional loci across the different diseases and traits.
The number of pleiotropic SNPs with conjFDR trait1& trait2< 0.05 were calculated per pheno-
type pair, and illustrated using a color scale. Thus, colors shown on the diagonal reflect the
number of the pleiotropic SNPs for a given lipid parameter and a specific immune-mediated
disease. The off-diagonal elements indicate the number of SNPs showing three-way pleiotropy
across the given lipid phenotype and a pair of different immune-mediated diseases.
Comparison with standard analytical approaches. To further evaluate our method, we
compared our results to findings from conventional approaches. In a ‘confirmation analysis’,
we calculated the fraction of SNPs identified with our FDR approach (condFDR< 0.01) that
remained significant (p< 5 x 10–8) in the recently published larger blood lipid GWAS[28]
compared with standard GWAS analysis methods (Figure Q in S1 File). We additionally com-
pared the number of pleiotropic SNPs identified by our conjunctional FDR method to those
identified by the standard GWAS approach, i.e., SNPs with p value< 5 x 10–8 for both blood
lipids and immune-mediated diseases. Further, we investigated the direction of effect of these
‘pleiotropic’ SNPs by plotting the z-scores between blood lipid and immune-mediated diseases.
In Tables H-J in S1 File, we display all loci with a conjunction of FDRtrait1& trait2< 0.05 in
Fig 2. ‘Conjunctional FDRManhattan plot’ of conjunctional (FDR<0.05) values for low density lipoprotein.Conjunctional—log10(FDR) values for low
density lipoproteins (LDL) cholesterol and Crohn’s Disease (CD), ulcerative colitis (UC), rheumatoid arthritis (RA), type 1 diabetes (T1D), celiac disease
(CeD), psoriasis (PSOR) and G) sarcoidosis (SARC) were plotted along their chromosome locations. SNPs with conjunctional FDR < 0.05 (i.e.,—log10
FDR > 1.3) are shown with enlarged data points. A black circle around the enlarged data points indicates the most significant SNP in each LD block and this
SNP was annotated with the closest gene which is listed above the symbols in each locus, except for the Major Histocompatibility Complex (MHC) region on
chromosome 6. The figure shows the localization of 87 LDL loci. Details for the associated loci outside of chromosome 6 are shown in Table F in S1 File.
doi:10.1371/journal.pone.0123057.g002
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blood lipids and immune-mediated diseases. The significance threshold of FDRtrait1& trait2
< 0.05 corresponds to five expected false positives per hundred reported associations. In Tables
Q-S in S1 File we show all ‘pleiotropic’ SNPs identified by standard GWAS.
Influence of MHC region on enrichment. The major histocompatibility complex (MHC)
is recognized as an important factor in the pathology of immune-mediated diseases. To exam-
ine the effect of the MHC for the conditional FDR analysis, we examined enrichment after re-
moving the SNPs in the MHC region. We removed all SNPs located in the MHC (location
25652429–33368333) on chromosome 6 and all SNPs in LD with such SNPs (r2> 0.2) then re-
peated the analyses described above.
Monogenic versus polygenic pleiotropy. To further investigate whether the observed
pleiotropy between lipids and immune-mediated diseases was driven by one or few large LD
blocks we reanalyzed the data using 100 random pruning. At each iteration, one SNP in every
LD block was randomly selected and the empirical cdfs were computed using the correspond-
ing p-values. These 100 CDF’s were averaged and used to generate conditional QQ plots (Fig-
ures R-T in S1 File).
Network analysis. For the construction of the gene and protein network, we considered
the 92 genes (or their gene products) in the previously confirmed 87 blood lipid loci associated
with either LDL, HDL or TG[14] as well as the 288 genes (or their gene products) in the novel
pleiotropic loci from the present analysis. In the gene network, each network edge represents
Fig 3. ‘Conjunctional FDRManhattan plot’ of conjunctional (FDR<0.05) values for high density lipoprotein. Conjunctional—log10(FDR) values for high
density lipoproteins (HDL) cholesterol and Crohn’s Disease (CD), ulcerative colitis (UC), rheumatoid arthritis (RA), type 1 diabetes (T1D), celiac disease
(CeD), psoriasis (PSOR) and G) sarcoidosis (SARC) were plotted along their chromosome locations. SNPs with conjunctional FDR < 0.05 (i.e.,—log10
FDR > 1.3) are shown with enlarged data points. A black circle around the enlarged data points indicates the most significant SNP in each LD block and this
SNP was annotated with the closest gene which is listed above the symbols in each locus, except for the Major Histocompatibility Complex (MHC) region on
chromosome 6. The figure shows the localization of 52 HDL loci. Details for the associated loci outside of chromosome 6 are shown in Table G in S1 File.
doi:10.1371/journal.pone.0123057.g003
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strong functional similarity of two genes based on their Gene Ontology annotations. The func-
tional similarity is computed by the rfunSim measure, which considers the Biological Process
and Molecular Function ontologies of the Gene Ontology[31]. The rfunSim similarity values
above the recommended cutoff 0.8 were retrieved from the FunSimMat web service[32]. In the
protein network, network edges represent physical protein-protein interactions extracted from
the iRefIndex database (release 10.0)[33]. Enriched KEGG pathways [34] were identified for
the genes/proteins in the respective networks by the GO-Elite software using the default pa-
rameters[35]. The resulting networks were visualized with Cytoscape[36] and the MultiColor-
edNodes plugin[37].
Results
Significant genetic overlap between blood lipids and immune-mediated
diseases
The conditional Q-Q plots revealed strong polygenic pleiotropic enrichment between TG and
CD, UC, RA, T1D, CeD, PSOR, with somewhat weaker enrichment with SARC (Figure A in
S1 File). Similar results were observed for LDL (Figure B in S1 File). A different pattern of en-
richment emerged for HDL, where strong pleiotropic enrichment was observed with CD, UC
and RA; weaker enrichment with T1D, and little enrichment with CeD, PSOR and SARC
(Figure C in S1 File). We also illustrate the high level of polygenic pleiotropic enrichment in
blood lipids (TG, LDL, HDL) with the immune-mediated diseases using “Enrichment
Plots”[38] (Figures D-F in S1 File). Further, the random pruning analysis showed that the en-
richment was not driven by large LD blocks (Figures R-T in S1 File). The lack of enrichment
between the blood lipids and CPD (Figure P in S1 File) showed that the polygenic overlap is
not general for all phenotypes.
Shared susceptibility loci for blood lipids and immune-mediated
disorders
To provide a comprehensive, unselected map of pleiotropic loci between blood lipids and im-
mune-mediated disorders, we performed a conjunction FDR analysis and constructed conjunc-
tion FDRManhattan plots (Figs 1, 2 and 3). Based on conjFDR< 0.05, we detected
independent pleiotropic loci between immune-mediated diseases and TG (n = 88), LDL
(n = 87) and HDL (n = 52) after pruning (based on LD r2>0.2) excluding loci located in MHC
region. The most significant pleiotropic loci (conjFDR< 0.01) for each blood lipid phenotype
(non-MHC loci) are listed in Tables E-G in S1 File, and all loci are listed in Tables H-J in
S1 File(conjFDR< 0.05). As can be seen from Figs 1, 2 and 3, pleiotropic loci were detected on
almost all chromosomes. There were 6 HDL, 6 LDL and 5 TG pleiotropic loci that were associ-
ated with several phenotypes (Tables H-J in S1 File). The direction of effect (z-scores) for the
SNPs with conjFDR<0.01 are presented in Tables K-M in S1 File. The directionality of effect
was fairly consistent across the blood lipids and the different immune-mediated diseases,
shown by positive correlations between blood lipids (TG, LDL, HDL) and CD, UC, RA and
PSOR and negative correlations between the blood lipids and CeD and SARC (Table N in
S1 File).
Patterns of genetic overlap between blood lipids and immune-mediated
diseases
Heat maps of the number of conjunctional loci revealed differences in the pattern of genetic
overlap between the three blood lipids and the seven immune-mediated diseases (Figure M in
Pleiotropy Immune and Lipid Pathobiology
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S1 File). LDL showed a number of overlapping SNPs with each of the immune-mediated dis-
eases except for SARC (as can be seen by the squares on the diagonal of Figure M in S1 File).
Examination of results off the diagonal elements indicated extensive common association
among TG, RA, T1D, CeD, and PSOR. A similar pattern of common SNPs clusters was ob-
served for LDL. HDL, however, showed a different pattern of genetic overlap, primarily involv-
ing inflammatory bowel diseases (CD and UC), and to a lesser degree RA and T1D. As was the
case with LDL and TG, there was little overlap with SARC.
Influence of MHC region on enrichment
To test the hypothesis that the observed enrichment pattern between blood lipids and im-
mune-mediated diseases may be driven solely by the MHC region, we examined enrichment
after removing SNPs in the MHC region. As illustrated in Figures G, H, J and K in S1 File we
found a slight decrease in enrichment between TG and T1D, CeD, PSOR and SARC, and be-
tween LDL and RA, CeD and SARC. However, there was almost no reduction in enrichment
between HDL and the immune-mediated diseases (Figures I and L in S1 File). Three-way heat
maps based on the non-MHC results illustrated that the pleiotropy between HDL and other
immune diseases was highly polygenic and not driven by the MHC region, whereas both LDL
and TG demonstrated less non-MHC related polygenic pleiotropy (Figure N in S1 File).
Comparison with conventional approaches
Number of conditional loci. To further compare our pleiotropic approach with standard
GWAS methods for detecting novel polymorphisms, we evaluated the number of blood lipid-
associated loci using conditional FDR. To estimate the number of independent loci, we pruned
the significantly associated SNPs and identified 570 gene loci with a significance threshold of
conditional FDR< 0.01 (Tables B-D in S1 File), including 166 with TG, 195 with LDL and 209
with HDL. Of these 127 were associated with more than one blood lipid phenotype, yielding
443 unique blood lipid loci (for more details, see Results and Tables B-D in S1 File).
Number of pleiotropic loci. Table 1 shows the number of pleiotropic SNPs/gene loci
identified with our conjunctional FDR method (conjFDR< 0.05) compared with the standard
GWAS approach. When a SNP having conjFDR< 0.05 between one blood lipid trait and mul-
tiple immune-mediated diseases, we selected the immune-mediated disease showing the mini-
mal conjFDR as the primary conjunctional phenotype. The number of pleiotropic SNPs in
Table 1 indicates the overlapping loci between blood lipids and the primary immune-mediated
disease. Across all evaluated lipid and immune-mediated phenotypes, our method increased
the number of pleiotropic SNPs dramatically compared with the standard GWAS approach.
TG showed the largest number of pleiotropic SNPs with immune-mediated diseases by both
our method and the standard GWAS approach. On the other hand, LDL showed the fewest
number of pleiotropic loci (Table 1 and Tables Q-S in S1 File). We also investigated the direc-
tion of these pleiotropic SNPs. Though there was no general patterns of directionality, SNPs
having a large effect in CeD showed opposite direction of effect on all three blood lipid
Table 1. Comparison of number of ‘pleiotropic’ SNPs with standard GWAS approach.
Lipid CD UC RA T1D CeD PSOR SARC
HDL 20(245;40) 16(107;17) 0(105;16) 0(75;18) 0(18;6) 0(2;1) 0(0)
LDL 1(134;29) 7(16;9) 13(417;66) 11(287;69) 7(57;24) 0(171;44) 0(0;0)
TG 0(205;23) 4(73;11) 37(678;95) 14(134;38) 24(25;13) 16(299;75) 0(0;0)
doi:10.1371/journal.pone.0123057.t001
Pleiotropy Immune and Lipid Pathobiology
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phenotypes; SNPs having larger effect in RA showed the same direction of effect in TG and
HDL (Figures X-Z in S1 File).
Comparison of the number of ‘pleiotropic’ SNPs/loci identified by standard GWAS and by
conjFDR between lipid and immune-mediated diseases. Numbers in each cell indicate ‘pleio-
tropic’ SNPs from GWAS (p< 5 x10-8 for both lipid and immune phenotypes, corresponding-
ly), from conjuctional FDR (conjFDR< 0.05; first number in parenthesis) and number of
pruned loci (LD r2> 0.2; second number in parenthesis). As illustrated, compared with a con-
ventional GWAS approach, conjFDR identified a larger number of pleotropic loci across all
evaluated lipid and immune-mediated phenotypes. Triglycerides (TG), low density lipopro-
teins (LDL) cholesterol, high density lipoproteins (HDL) cholesterol and Crohn’s Disease
(CD), ulcerative colitis (UC), rheumatoid arthritis (RA), type 1 diabetes (T1D), celiac disease
(CeD), psoriasis (PSOR) and sarcoidosis (SARC).
Confirmation analysis. The confirmation analysis using the larger recently published
blood lipid GWAS[28] showed that reordering the SNPs according to conditional FDR results
in an equal or better replication rate compared to the unconditional p-value ranking using the
standard GWAS method, indicating that our FDR approach performs comparably to conven-
tional methods (Figure Q in S1 File). The corresponding p-values from the larger GWAS are
included in Tables B-D in S1 File.
Shared biological pathways between blood lipids and immune-mediated
diseases
The biological relationships between pleiotropic loci identified with the new methodology were
compared with that of loci previously shown to be associated with blood lipids using standard
approaches[14], applying functional gene networks and protein interaction networks as well as
biological pathway enrichment analysis. Notably, the connectivity among the loci in the com-
bined network increased considerably compared to the networks represented by pleiotropic
loci and by blood lipid loci only (Fig 4). This demonstrates biological relatedness between
pleiotropic loci from the present analysis and blood lipid loci from previous reports[14]. In
case of the functional gene network, a 40% increase in the number of network nodes represent-
ing blood lipid loci was observed compared to previous results (Fig 4). Furthermore, as revealed
by the protein interaction network, the loci representing known hypercholesterolemic mouse
models (e.g. APOE [MIM 107741] and LDLR [MIM 606945]) showed only a limited functional
overlap with the pleiotropic loci (Figure O in S1 File). Enriched KEGG pathways represented
by the pleiotropic loci include biological functions related to glycosphingolipid synthesis (e.g.
FUT2 [MIM 182100]) and to intestinal host-microbe interactions (e.g. ATG16L1 [MIM
610767]) (Figure O in S1 File). Multiple enriched pathways for the pleiotropic loci also associ-
ate with cancer development (Figure O in S1 File).
Discussion
Our findings indicate abundant polygenic overlap between blood lipid levels and immune-me-
diated diseases. Leveraging the association with immune-mediated diseases, we detected shared
gene loci between these immune-mediated diseases and TG (n = 88 loci), LDL (n = 87 loci) and
HDL (n = 52 loci). The variation in the genetic overlap for each observed immune-mediated
disease group suggests differential underlying biological mechanisms for CD/UC, RA, T1D,
CeD, SARC and PSOR. Pathway analysis showed little pleiotropy with core lipoprotein sys-
tems, but implicated multiple novel biological mechanisms of combined relevance concerning
immune pathogenesis and lipid biology, which potentially also could include the gut
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microbiota as a possible common denominator for some of the shared mechanisms[39]. These
findings may have implications for therapeutic strategies in immune and lipid-mediated
diseases.
Our findings indicate polygenic overlap between blood lipids and immune-mediated diseases.
Associations of some RA susceptibility genes with lipid levels have previously been reported[40],
and overlap of individual gene loci between blood lipids and immune-mediated diseases has
been previously recognized[8]. In addition, prior data have identified genes associated with lipid
traits and inflammatory phenotypes. GWAS of the inflammatory biomarker C-reactive protein
(CRP), identified several genes involved in metabolic syndrome, weight homeostasis, and prema-
ture atherothrombosis[41]. These pathways were confirmed in a recent meta-analysis of CRP
Fig 4. Functional gene network for novel pleiotropic loci from the present analysis and previously confirmed blood lipid loci. The protein-coding
genes closest to the most associated SNP in the pleiotropic loci and the previously confirmed blood lipid loci were used to construct a functional similarity
network of genes (see Methods). The network contains 158 gene nodes that are connected by 509 similarity edges. Genes previously reported to associate
with blood lipids are represented by turquoise nodes (or turquoise node sectors). Red nodes (or red node sectors) represent pleiotropic loci between immune
mediated diseases and Triglycerides (TG). Green nodes (or green node sectors) represent pleiotropic loci between immune-mediated diseases and low
density lipoproteins (LDL) cholesterol. Purple nodes (or purple node sectors) represent pleiotropic loci between immune-mediated diseases and high density
lipoproteins (HDL) cholesterol. Solid grey and orange edge lines indicate strong functional similarity between the connected genes based on their Gene
Ontology annotations. Orange edge lines correspond to the 212 novel connections between nodes in the pleiotropic loci network and blood lipid loci network.
Diamond node shapes represent the 23 new genes that arise after combining the pleiotropic loci and blood lipid loci into one network. Enriched KEGG
pathways (see Tables O-P in S1 File) are connected to respective gene nodes with dotted pink lines. Genes and their nodes that are not connected to any
other node in the network (48 genes) or annotated (82 genes) are omitted from the figure.
doi:10.1371/journal.pone.0123057.g004
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GWAS, highlighting pleiotropy between immune response and metabolic regulatory pathways
[42]. However, the extent of this pleiotropy may have been previously underestimated, since the
polygenic pleiotropy between immune and lipid phenotypes was not identified. Further, several
clinical and epidemiological studies have reported an association between blood lipids and indi-
vidual immune-mediated diseases[1–5]. For example, CD and UC have been associated with low
levels of HDL and high levels of LDL cholesterol[2,43,44]. However, the bases of these associa-
tions are difficult to discern when they are observed within the same individual, since both con-
ditions may arise from shared environmental influences, or one condition may cause the other,
with ambiguity in directionality of causation. Results from the current genetic epidemiology-
based approach, in which shared genetic overlap was identified across separate study popula-
tions, strongly suggest that at least some of the phenotypic association arises from a shared ge-
netic basis. Based on the selection criteria, it is unlikely that patients with unrecognized
immune-related disorders were included in the blood lipids study population in large enough
numbers to affect the results. However, we cannot exclude the possibility that some participants
in the blood lipids population could develop immune-mediated disorders over time. In fact, as
we discuss below, the genetic results imply that this may be likely to occur in some individuals.
Further, the presence of overlapping genes between blood lipids and immune-related diseases
does not necessarily reflect ‘true’ genetic pleiotropy as this is defined as genes common to inde-
pendent phenotypes, which are not co-morbid. Instead, the shared loci presented here may be
associated with overlapping pathophysiological mechanisms and additional experimental work
is needed to further elucidate the biological underpinnings of these findings.
Leveraging the polygenic overlap between immune-mediated diseases and blood lipids, our
findings identify novel loci associated with blood lipids. Compared with a conventional GWAS
approach (p< 5 x10-8 for both lipid and immune phenotypes), we found that conjunctional
FDR identified a larger number of pleotropic loci across all evaluated lipid and immune pheno-
types. The z-scores suggest that the direction of effect varies—some gene loci increase risk of
both phenotypes whereas others show opposing effects in the two phenotypes. Applying the
conditional FDR approach, we used the signal in the associated phenotype to boost the discov-
ery of blood lipid risk factors. Building upon our prior work[15–21], compared with a conven-
tional FDR approach, we identified 374 additional blood lipid-associated SNPs using our
conditional FDR method indicating that genetic overlap can improve statistical power for gene
discovery. One potential concern relates to whether these novel analysis methods lower the sta-
tistical threshold (sensitivity) for novel SNP identification without improving the likelihood of
detecting true findings (specificity). The present findings of increased confirmation rate in the
larger blood lipid GWAS[28] of our conditional FDR approach compared to the standard
GWAS methods suggest a reduced likelihood of type I error. Importantly, these findings illus-
trate that rather than lowering the statistical threshold, the current approach of re-ranking
SNPs using pleiotropy identifies those variants that are more likely to replicate in independent
samples (true positives). We have previously shown that genetic loci in cancer, brain related
and cardiovascular phenotypes identified with our methods replicate at the same or higher rate
as standard methods[15–17,19,20], and that these methods result in improved sensitivity for a
given specificity[19]. It is important to note that few, if any, of our conjunctional loci (as indi-
cated in Figures X-Z and Tables Q-S in S1 File) reached a traditional level of statistical signifi-
cance within a genome-wide context and additional replication in independent cohorts is
needed. However, for polygenic phenotypes, including cardiovascular and immune-mediated
diseases, a single phenotype approach using standard approaches, i.e. Bonferroni-corrected sig-
nificance thresholds, may not sufficiently explain phenotypic variance[15] or sufficiently iden-
tify shared genetic risk factors.
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The polygenic overlap between blood lipids and immune-mediated disorders suggested by
the present findings may inform novel pathogenic aspects of atherosclerosis, a chronic inflam-
matory process of the arterial wall, initiated by subsequent subendothelial accumulation of
blood lipids[45]. Experimental evidence supports a key role for inflammation in atherosclerotic
plaque formation, and the increased events of atherosclerosis in patients with chronic inflam-
matory rheumatic disorders[46,47] further support a role for inflammation in atherogenesis.
In this context, the current findings of a polygenic link between lipid and inflammatory biology
are likely to be relevant, suggesting that the well recognized bidirectional interaction between
inflammatory and lipid pathways in atherogenesis may in fact involve some commen genetic
factors between these pathways. Additional pathogenic insight from the novel loci is empha-
sized by the network analysis because loci related to known hypercholesterolemic mouse mod-
els (i.e. Apoe−/− and Ldlr−/−mice) show limited functional overlap with the pleiotropic loci.
Further, recent evidence suggest that lipids may play a specific role in the local disruption of
the epithelial barrier, including intestinal mucosa, in inflammatory disorders[48]. The present
findings further implicate abnormal lipid biology in the disease mechanisms of CD, UC and
CeD. The strong polygenic pleiotropy between lipids and T1D also supports a role of lipid
pathobiology, as shown in relation to insulin secretion[49], diabetes risk[50] and pathology
[51]. The current findings of statistical associations must be followed by experimental work to
determine the specific underlying biology. The present results will be helpful for guiding the ex-
perimental work in direction of genes with potential involvement in disease mechanism.
Although we found an overlap between genetic risk factors for immune-mediated diseases
and blood lipids, the specific loci involved for each trait differed. Recent findings suggest a
common genetic basis for a number of immune-mediated diseases[52]. However, the pattern
of genetic overlap for individual traits differs but has been poorly delineated. In the present
analysis, there was a strong polygenic pleiotropic enrichment between TG and LDL and most
of the examined immune-mediated disorders, whereas genetic overlap with HDL was primarily
found for CD, UC and RA. Furthermore, we found a differential effect of the MHC region on
immune-mediated enrichment on HDL compared with TG and LDL: removal of the MHC re-
gion resulted in significant enrichment attenuation in TG and LDL but not HDL. This suggests
that the overlap between HDL and immune-mediated diseases is more polygenic and driven by
non-MHC genetic regions whereas the MHC locus likely accounts for a large portion of the
pleiotropy between LDL/TG and immune-mediated diseases. For SARC, little polygenic pleio-
tropic enrichment was found for either of the three blood lipid parameters. Whether this re-
flects a lower risk for development of cardiovascular disease in SARC relative to the other
immune-mediated disorders is a question that merits further study. The current analytical ap-
proach depends on the power of the different GWAS samples. Thus, we must be careful when
comparing results that are obtained from GWAS with different sample sizes. This is of particu-
lar concern for SARC, which has a much smaller sample size than several of the other GWAS.
Our findings suggest that there are underlying genetic risk factors that interplay with envi-
ronment across all of these diseases. A striking risk locus in this regard is rs968567 linked to
fatty acid desaturase 2 (FADS2 [MIM 606149]). In the network analysis, FADS2 connects with
FADS1([MIM 606148]) and FADS3([MIM 606150]) as well as CYP7A1([MIM 118455]), the
rate limiting enzyme in bile acid synthesis. By the introduction of double bands, some of these
FADS play a key role in the formation of omega-6 and omega-3 polyunsaturated FA (PUFAs),
such as eicosopentaenoic, docosahexaenoic acids and arachidonic acid derived from the dietary
intake of essential FA[53,54]. The FADS2 polymorphism (rs968567) is located in the promoter
region of the gene and may affect the binding of a transcription factor, ELK1([MIM 311040])
[53]. Variant status may impact FADS2 expression and consequently the levels of PUFAs with-
in cells and the inflammatory signalling through eicosanoids, and these pathway have been
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suggested as resolving mediators in chronic inflammatory disorders like atherosclerosis and
the investigated immune-mediated disorders[55]. Further evidence for gene-environment in-
teractions potentially underlying parts of the observed pleiotropy stems from the strong associ-
ations at 6p21 (MHC) as well as from the network analysis. One network cluster associates
with the FUT2 gene, which is a susceptibility gene for CD that contributes to the composition
of the gut microbial community even in individuals without inflammatory bowel disease[39].
The gut microbial metabolism likely needs to be considered an integral part of the host metab-
olism of bile acids and short-chain fatty acids[56]. Bile acids are metabolized by intestinal bac-
teria and some of these metabolites are ligands for the farnesoid X receptor which regulates
cholesterol, triglyceride and bile acid synthesis[39]. Consequently, alterations in the gut micro-
biota are likely to influence the regulation of bile acids and lipids metabolism[56], and bacterial
derived bile acids predict response of statin treatment in humans[57]. Notably, changes in the
gut microbiota are linked to the inflammatory status of patients with atherosclerosis[58], and
some antibiotics possess lipid-lowering effects[59]. Recently, phosphatidylcholine metabolism,
which is related to glycosphingolipid synthesis (FUT2), was implicated in atherosclerosis risk
[60]. Altogether, several lines of evidence suggest that future experimental and genetic studies
should incorporate assessments related to gene-microbial interactions and dietary intake of lip-
ids[60,61].
This work has clinical implications. Our data further support the notion that among indi-
viduals with cardiovascular risk factors, immune and inflammatory status should be monitored
and patients with immune-mediated disorders should be screened for abnormal blood lipid
levels[22]. These findings also suggest the need for further investigating the role of lipid lower-
ing drugs such as statins in patients with immune-mediated and inflammatory disorders. Such
treatments could not only prevent the development of cardiovascular disorders, but could po-
tentially influence autoimmunity and inflammation in these patients. It is tempting to hypothe-
size that those apparently healthy individuals with high load of these shared risk genotypes,
predisposing for inflammation and lipid disturbances, could be at particularly high risk for de-
veloping cardiovascular disorders. Further prospective studies in these individuals could clarify
these issues. There is some evidence indicating that anti-rheumatic drugs affect lipid profiles
[62], and that cholesterol lowering drugs (statins) reduce risk of [63], suggesting that novel
treatment regimens may evolve from the exploration of pathogenic mechanisms influenced by
pleiotropic disease loci.
To conclude, we show abundant genetic overlap between blood lipids and a selection of
archetypical immune-mediated disorders and identify a range of shared loci across the genome.
These findings strongly support interactions between the immune system and lipid biology in
human disease which may have implications for therapeutic trials involving lipid-lowering and
anti-inflammatory agents.
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